ALPMY : Summary for ASTELLAS PHARMA UNSP ADR EACH R - Yahoo Finance

U.S. Markets closed

Astellas Pharma Inc. (ALPMY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
13.45+0.08 (+0.60%)
At close: 3:57PM EST
People also watch
VIVHYTKPYYCFRUYEQCDSNKY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close13.38
Open13.44
Bid0.00 x
Ask0.00 x
Day's Range13.37 - 13.49
52 Week Range12.50 - 19.40
Volume101,826
Avg. Volume183,459
Market Cap28.59B
Beta0.43
PE Ratio (TTM)15.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.30 (2.17%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube2 days ago

    ETFs with exposure to Astellas Pharma, Inc. : January 20, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Astellas Pharma, Inc. Here are 5 ETFs with the largest exposure to ALPMY-US. Comparing the performance and risk of Astellas Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswirelast month

    Astellas to Present at J.P. Morgan Healthcare Conference

    NORTHBROOK, Ill., Dec. 21, 2016 /PRNewswire/ -- Astellas US, LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the company's global President and CEO Yoshihiko Hatanaka will ...

  • PR Newswirelast month

    Astellas Completes Acquisition of Ganymed Pharmaceuticals

    TOKYO, Dec. 21, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals AG ("Ganymed"), a biopharmaceutical company located in Mainz, Germany, and Ganymed has become a wholly owned subsidiary of Astellas as of CET December 20, 2016. Under the agreement executed between Astellas and Ganymed's shareholders, Astellas paid EUR 422 million to acquire 100% of the equity in Ganymed.